ERJ- A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4, incl. discussion and Q&A - Amsterdam 2025

From the editors' desk

Chair(s): Raffaella Nenna, Darren Taichman, James D. Chalmers

Session type: Journal session

ERJ- A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4, incl. discussion and Q&A

Dave Singh

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

ERJ- A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4, incl. discussion and Q&A

Dave Singh

Replay

Slides

NEJM- Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules, incl. discussion and Q&A

Fabien Maldonado

Replay

Slides

ERJ- A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA; incl. discussion and Q&A

Ioana R Preston

Replay

Slides

NEJM- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis, incl. discussion and Q&A

James D. Chalmers

Replay

Slides

Session aims

To discuss the latest high impact published data from the ERJ and the NEJM. We will present 4 recently published/accepted papers covering diverse topics in respiratory medicine

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}